NO2119726T3 - - Google Patents

Info

Publication number
NO2119726T3
NO2119726T3 NO08008944A NO08008944A NO2119726T3 NO 2119726 T3 NO2119726 T3 NO 2119726T3 NO 08008944 A NO08008944 A NO 08008944A NO 08008944 A NO08008944 A NO 08008944A NO 2119726 T3 NO2119726 T3 NO 2119726T3
Authority
NO
Norway
Application number
NO08008944A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2119726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2119726T3 publication Critical patent/NO2119726T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO08008944A 2008-05-14 2008-05-14 NO2119726T3 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08008944.4A EP2119726B2 (en) 2008-05-14 2008-05-14 Novel and powerful MHC-class II peptides derived from survivin and neurocan

Publications (1)

Publication Number Publication Date
NO2119726T3 true NO2119726T3 (OSRAM) 2015-05-23

Family

ID=39789337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08008944A NO2119726T3 (OSRAM) 2008-05-14 2008-05-14

Country Status (24)

Country Link
US (5) US8647629B2 (OSRAM)
EP (3) EP2119726B2 (OSRAM)
JP (1) JP5663473B2 (OSRAM)
KR (2) KR101602024B1 (OSRAM)
CN (1) CN102027006B (OSRAM)
AU (1) AU2009248413B2 (OSRAM)
BR (2) BRPI0912622A2 (OSRAM)
CA (1) CA2724198C (OSRAM)
CY (2) CY1115999T1 (OSRAM)
DK (2) DK2119726T5 (OSRAM)
EA (1) EA019603B1 (OSRAM)
ES (2) ES2532896T5 (OSRAM)
HK (1) HK1209757A1 (OSRAM)
HR (2) HRP20151135T4 (OSRAM)
HU (2) HUE024541T2 (OSRAM)
MX (1) MX2010012443A (OSRAM)
NO (1) NO2119726T3 (OSRAM)
NZ (1) NZ588605A (OSRAM)
PL (2) PL2119726T5 (OSRAM)
PT (2) PT2119726E (OSRAM)
RS (1) RS53872B2 (OSRAM)
SI (2) SI2119726T2 (OSRAM)
UA (1) UA103481C2 (OSRAM)
WO (1) WO2009138236A1 (OSRAM)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
JP5352586B2 (ja) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
PT3050576T (pt) 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
LT2512450T (lt) 2009-12-15 2018-04-25 Ascendis Pharma Endocrinology Division A/S Sausa augimo hormono kompozicija, laikinai prijungta prie polimero nešiklio
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9109007B2 (en) * 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
NZ609916A (en) * 2010-12-14 2015-03-27 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN102181401B (zh) * 2011-02-01 2013-04-24 北京市肿瘤防治研究所 存活素酶联免疫试剂盒及其应用
JP6512568B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
WO2015066057A2 (en) * 2013-10-28 2015-05-07 Baylor College Of Medicine Expansion of cmv-specific t cells from cmv-seronegative donors
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
CA2968282A1 (en) 2014-11-18 2016-05-26 Thomas Kurpiers Polymeric hgh prodrugs
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
PH12021550850A1 (en) * 2015-03-27 2022-10-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA42294B1 (fr) * 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
CA3221001A1 (en) * 2015-07-06 2017-01-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY198087A (en) * 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US20200237819A1 (en) * 2016-06-28 2020-07-30 Geneius Biotechnology, Inc. T cell compositions for immunotherapy
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CR20210128A (es) 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
IL268920B2 (en) 2017-03-03 2025-05-01 Treos Bio Zrt Peptide vaccines
WO2019007974A1 (en) * 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
PE20200693A1 (es) 2017-07-07 2020-06-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres
EP3694541A2 (en) 2017-10-09 2020-08-19 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
CN111556757A (zh) 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
CA3100074A1 (en) * 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Peptide activating agent
US12134663B2 (en) 2018-05-15 2024-11-05 Interk Peptide Therapeutics Limited Cationic peptides for activating Lck
US11666644B2 (en) 2018-09-04 2023-06-06 Treos Bio Limited Peptide vaccines
US12303553B2 (en) 2019-03-04 2025-05-20 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
SI4021487T1 (sl) 2019-11-15 2024-03-29 Enterome S.A., Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti
CN113045635B (zh) * 2019-12-26 2025-12-16 上海细胞治疗集团股份有限公司 一种特异性结合hla-a2分型的多肽组合物及应用
KR20220167288A (ko) * 2020-04-14 2022-12-20 유니버시떼 드 몬트리얼 급성 골수성 백혈병(aml)에 대한 신규한 종양-특이적 항원 및 이의 용도
EP4247410A4 (en) 2020-11-19 2025-05-07 KaliVir Immunotherapeutics, Inc. ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL
JP7661734B2 (ja) * 2021-03-19 2025-04-15 日本電気株式会社 検査システム及び検査方法
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
US20250125005A1 (en) * 2021-08-17 2025-04-17 Intomics A/S Vaccine design pipeline
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US6274362B1 (en) * 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
KR20040065260A (ko) 2001-12-13 2004-07-21 코닌클리케 필립스 일렉트로닉스 엔.브이. 매체 시스템상의 매체 콘텐츠 추천
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
JP2005537800A (ja) * 2002-09-06 2005-12-15 マンカインド コーポレイション エピトープ配列
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
JP2007519910A (ja) * 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
US7618816B2 (en) † 2005-11-09 2009-11-17 Ontherix, Inc. Metal-binding therapeutic peptides
JP5352586B2 (ja) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
DK2119726T5 (en) † 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera

Also Published As

Publication number Publication date
NZ588605A (en) 2012-06-29
US8647629B2 (en) 2014-02-11
CY1117171T1 (el) 2017-04-05
KR20110021881A (ko) 2011-03-04
RS53872B1 (sr) 2015-08-31
HRP20150300T1 (hr) 2015-04-24
PT2119726E (pt) 2015-03-30
HRP20150300T4 (hr) 2018-03-09
CA2724198A1 (en) 2009-11-19
DK2291395T3 (da) 2015-09-21
PT2291395E (pt) 2015-10-23
KR20130041375A (ko) 2013-04-24
KR101602024B1 (ko) 2016-03-09
SI2119726T1 (sl) 2015-05-29
AU2009248413A1 (en) 2009-11-19
EP2291395A1 (en) 2011-03-09
AU2009248413B2 (en) 2014-07-17
RS53872B2 (sr) 2018-06-29
EP2899206A1 (en) 2015-07-29
PL2291395T5 (pl) 2019-04-30
SI2291395T1 (sl) 2015-10-30
US20200078439A1 (en) 2020-03-12
SI2119726T2 (en) 2018-03-30
PL2119726T3 (pl) 2015-05-29
US11957729B2 (en) 2024-04-16
BR122019014468B1 (pt) 2020-09-15
HUE024541T2 (hu) 2016-01-28
CA2724198C (en) 2016-03-22
ES2549088T3 (es) 2015-10-22
EP2119726B2 (en) 2017-11-29
HRP20151135T1 (hr) 2015-11-20
US9498512B2 (en) 2016-11-22
HK1209757A1 (en) 2016-04-08
DK2119726T5 (en) 2018-03-26
EA019603B1 (ru) 2014-04-30
ES2532896T3 (es) 2015-04-01
WO2009138236A1 (en) 2009-11-19
CY1115999T1 (el) 2017-01-25
HUE028102T2 (en) 2016-11-28
EP2119726B1 (en) 2014-12-24
HRP20151135T4 (hr) 2019-03-08
MX2010012443A (es) 2010-12-20
US10434136B2 (en) 2019-10-08
UA103481C2 (ru) 2013-10-25
KR101509284B1 (ko) 2015-04-10
CN102027006B (zh) 2016-01-13
DK2119726T4 (en) 2018-02-19
US20100029571A1 (en) 2010-02-04
DK2119726T3 (en) 2015-02-16
EA201071297A1 (ru) 2011-04-29
BRPI0912622A2 (pt) 2016-05-03
JP2011520436A (ja) 2011-07-21
US20140127242A1 (en) 2014-05-08
PL2119726T5 (pl) 2018-04-30
US20140086943A1 (en) 2014-03-27
CN102027006A (zh) 2011-04-20
EP2291395B2 (en) 2018-11-14
ES2549088T5 (es) 2019-04-29
US20130323272A1 (en) 2013-12-05
SI2291395T2 (sl) 2019-03-29
EP2291395B1 (en) 2015-08-12
BR122019014468B8 (pt) 2021-07-27
HK1156323A1 (en) 2012-06-08
PL2291395T3 (pl) 2016-01-29
JP5663473B2 (ja) 2015-02-04
EP2119726A1 (en) 2009-11-18
DK2291395T4 (en) 2019-02-18
ES2532896T5 (es) 2018-03-20

Similar Documents

Publication Publication Date Title
BRPI0917573A2 (OSRAM)
BRPI0918697A2 (OSRAM)
BRPI0917525A2 (OSRAM)
NO2119726T3 (OSRAM)
BRPI0920750A2 (OSRAM)
BRPI0919470A2 (OSRAM)
BRPI0922455A2 (OSRAM)
BRPI0923734A2 (OSRAM)
BRPI0917618A8 (OSRAM)
BRPI0912727A2 (OSRAM)
BRPI0922669A2 (OSRAM)
BRPI0914750A2 (OSRAM)
BRPI0910485A2 (OSRAM)
BRPI0919811A2 (OSRAM)
BRPI0915616A2 (OSRAM)
BRPI0912462A2 (OSRAM)
BRPI0920914A2 (OSRAM)
BRPI0922550A2 (OSRAM)
BRPI0916284A2 (OSRAM)
BRPI0911617A2 (OSRAM)
BRPI0913605A2 (OSRAM)
BRPI0914852A2 (OSRAM)
BRPI0910572A2 (OSRAM)
CH2347250H2 (OSRAM)
BRPI0914820A2 (OSRAM)